ArticleBritish journal of cancer2016

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Angus G Dalgleish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.